{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:42:58Z","timestamp":1794534178164,"version":"4.9.1"},"reference-count":271,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41577-026-01312-3","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:26:16Z","timestamp":1780395976000},"page":"799-816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hallmarks and correlates of effective adoptive cell immunotherapy for cancer"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4994-3758","authenticated-orcid":false,"given":"Sri","family":"Krishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Lowery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8939-8910","authenticated-orcid":false,"given":"Steven A.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"1312_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45307-x","volume":"15","author":"K Mani","year":"2024","unstructured":"Mani, K. et al. Causes of death among people living with metastatic cancer. Nat. Commun. 15, 1519 (2024).","journal-title":"Nat. Commun."},{"key":"1312_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1312_CR3","unstructured":"American Cancer Society. Cancer Facts & Figures 2024 (2024)."},{"key":"1312_CR4","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451\u20135458 (2014).","journal-title":"J. Immunol."},{"key":"1312_CR5","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1312_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"1312_CR7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal, V., Workman, C. J. & Vignali, D. A. A. LAG-3 as the third checkpoint inhibitor. Nat. Immunol. 24, 1415\u20131422 (2023).","journal-title":"Nat. Immunol."},{"key":"1312_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909\u2013915 (2004).","journal-title":"Nat. Med."},{"key":"1312_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","volume":"3","author":"MJ Lin","year":"2022","unstructured":"Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911\u2013926 (2022).","journal-title":"Nat. Cancer"},{"key":"1312_CR10","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri, G. et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J. Clin. Invest. 130, 5976\u20135988 (2020).","journal-title":"J. Clin. Invest."},{"key":"1312_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"1312_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"1312_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"1312_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"1312_CR15","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport, A. R. et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 30, 1013\u20131022 (2024).","journal-title":"Nat. Med."},{"key":"1312_CR16","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat. Med. 30, 1044\u20131053 (2024).","journal-title":"Nat. Med."},{"key":"1312_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362.e24 (2020).","journal-title":"Cell"},{"key":"1312_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"1312_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62\u201368 (2015).","journal-title":"Science"},{"key":"1312_CR20","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/s41591-019-0596-y","volume":"25","author":"TN Yamamoto","year":"2019","unstructured":"Yamamoto, T. N., Kishton, R. J. & Restifo, N. P. Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat. Med. 25, 1488\u20131499 (2019).","journal-title":"Nat. Med."},{"key":"1312_CR21","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/s41591-024-03109-0","volume":"30","author":"M Parkhurst","year":"2024","unstructured":"Parkhurst, M. et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. Nat. Med. 30, 2586\u20132595 (2024). This study demonstrates that TCR-T targeting patient-specific neoantigens can lead to objective clinical responses in patients with metastatic solid epithelial cancer.","journal-title":"Nat. Med."},{"key":"1312_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917\u2013924 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1312_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00035-1","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers. Nat. Rev. Drug Discov. 23, 238 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1312_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney, J. et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J. Immunother. Cancer 10, e005755 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1312_CR25","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik, A. A. et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J. Clin. Oncol. 39, 2656\u20132666 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1312_CR26","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1158\/1078-0432.CCR-21-1171","volume":"27","author":"SJ Seitter","year":"2021","unstructured":"Seitter, S. J. et al. Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin. Cancer Res. 27, 5289\u20135298 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR27","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","volume":"28","author":"ST Levi","year":"2022","unstructured":"Levi, S. T. et al. Neoantigen identification and response to adoptive cell transfer in anti-PD-1 na\u00efve and experienced patients with metastatic melanoma. Clin. Cancer Res. 28, 3042\u20133052 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR28","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113\u20132125 (2022). This study, along with Sarnaik et al. (2021), is one of the first clinical reports of TIL-ACT mediating durable clinical responses in patients with metastatic melanoma who were refractory to ICB therapies, leading to the approval of lifileucel.","journal-title":"N. Engl. J. Med."},{"key":"1312_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.09.015","volume":"32","author":"N Singh","year":"2024","unstructured":"Singh, N. Approval of the first TCR-based cell therapy. Mol. Ther. 32, 3195 (2024).","journal-title":"Mol. Ther."},{"key":"1312_CR30","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo, S. P. et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403, 1460\u20131471 (2024).","journal-title":"Lancet"},{"key":"1312_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong, D. S. et al. Autologous T cell therapy for MAGE-A4 solid cancers in HLA-A*02 patients: a phase 1 trial. Nat. Med. 29, 104\u2013114 (2023). This study, along with D\u2019Angelo et al. (2024), is one of the first clinical reports of TCR-T mediating durable clinical responses in patients with metastatic cancer, leading to the approval of afami-cel.","journal-title":"Nat. Med."},{"key":"1312_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707\u2013715 (2023).","journal-title":"Nature"},{"key":"1312_CR33","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-18-1494","volume":"9","author":"MR Parkhurst","year":"2019","unstructured":"Parkhurst, M. R. et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 9, 1022\u20131035 (2019).","journal-title":"Cancer Discov."},{"key":"1312_CR34","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","volume":"615","author":"C Puig-Saus","year":"2023","unstructured":"Puig-Saus, C. et al. Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature 615, 697\u2013704 (2023).","journal-title":"Nature"},{"key":"1312_CR35","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747\u2013752 (2013).","journal-title":"Nat. Med."},{"key":"1312_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2014-04-567933","volume":"124","author":"M Rajasagi","year":"2014","unstructured":"Rajasagi, M. et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 124, 453\u2013462 (2014).","journal-title":"Blood"},{"key":"1312_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018). This study demonstrates that the cell surface inhibitory marker CD39 is highly expressed on tumour-specific TIL in humans.","journal-title":"Nature"},{"key":"1312_CR38","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","volume":"31","author":"N van Rooij","year":"2013","unstructured":"van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439\u2013e442 (2013). This study, along with Robbins et al. (2013), is among the first reports of using next-generation sequencing of human tumours to identify candidates for neoantigen-specific T cell identification.","journal-title":"J. Clin. Oncol."},{"key":"1312_CR39","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016). This study demonstrates that TIL-ACT targeting a driver neoantigen (KRAS) leads to long-term response in a patient with epithelial cancer.","journal-title":"N. Engl. J. Med."},{"key":"1312_CR40","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641\u2013645 (2014). This study provides a documented clinical report of CD4+ neoantigen-specific TIL mediating durable clinical responses in a patient with metastatic cancer.","journal-title":"Science"},{"key":"1312_CR41","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724\u2013730 (2018).","journal-title":"Nat. Med."},{"key":"1312_CR42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.aak9510","volume":"356","author":"S Stevanovi\u0107","year":"2017","unstructured":"Stevanovi\u0107, S. et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science 356, 200\u2013205 (2017).","journal-title":"Science"},{"key":"1312_CR43","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","volume":"31","author":"FJ Lowery","year":"2025","unstructured":"Lowery, F. J. et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nat. Med. 31, 1994\u20132003 (2025).","journal-title":"Nat. Med."},{"key":"1312_CR44","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","volume":"10","author":"SP Kim","year":"2022","unstructured":"Kim, S. P. et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol. Res. 10, 932\u2013946 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"1312_CR45","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 386, 2112\u20132119 (2022). This study is one of the first \u2018off-the-shelf\u2019 TCR-T clinical reports targeting a shared KRAS driver-neoantigen.","journal-title":"N. Engl. J. Med."},{"key":"1312_CR46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ni.3682","volume":"18","author":"E Tran","year":"2017","unstructured":"Tran, E., Robbins, P. F. & Rosenberg, S. A. \u20180 common pathway\u2019 of human cancer immunotherapy: targeting random somatic mutations. Nat. Immunol. 18, 255\u2013262 (2017).","journal-title":"Nat. Immunol."},{"key":"1312_CR47","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1158\/0008-5472.CAN-18-0163","volume":"78","author":"S Krishna","year":"2018","unstructured":"Krishna, S. et al. Human papilloma virus specific immunogenicity and dysfunction of CD8+ T cells in head and neck cancer. Cancer Res. 78, 6159\u20136170 (2018).","journal-title":"Cancer Res."},{"key":"1312_CR48","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/jnci\/59.4.1227","volume":"59","author":"ML Kripke","year":"1977","unstructured":"Kripke, M. L., Lofgreen, J. S., Beard, J., Jessup, J. M. & Fisher, M. S. In vivo immune responses of mice during carcinogenesis by ultraviolet irradiation. J. Natl Cancer Inst. 59, 1227\u20131230 (1977).","journal-title":"J. Natl Cancer Inst."},{"key":"1312_CR49","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.1073\/pnas.92.17.7976","volume":"92","author":"PG Coulie","year":"1995","unstructured":"Coulie, P. G. et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl Acad. Sci. USA 92, 7976\u20137980 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1312_CR50","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.7652577","volume":"269","author":"T W\u00f6lfel","year":"1995","unstructured":"W\u00f6lfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281\u20131284 (1995). This study, along with Coulie et al. (1995), is one of the first reports of detecting neoantigen-specific T cells in patients with cancer.","journal-title":"Science"},{"key":"1312_CR51","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1084\/jem.183.6.2501","volume":"183","author":"D Br\u00e4ndle","year":"1996","unstructured":"Br\u00e4ndle, D., Brasseur, F., Weynants, P., Boon, T. & Van den Eynde, B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183, 2501\u20132508 (1996).","journal-title":"J. Exp. Med."},{"key":"1312_CR52","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1084\/jem.183.3.1185","volume":"183","author":"PF Robbins","year":"1996","unstructured":"Robbins, P. F. et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183, 1185\u20131192 (1996).","journal-title":"J. Exp. Med."},{"key":"1312_CR53","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko, V. & Rosenberg, S. A. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell 38, 454\u2013472 (2020).","journal-title":"Cancer Cell"},{"key":"1312_CR54","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463\u20131469 (2016).","journal-title":"Science"},{"key":"1312_CR55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"1312_CR56","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature24673","volume":"552","author":"G Germano","year":"2017","unstructured":"Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116\u2013120 (2017).","journal-title":"Nature"},{"key":"1312_CR57","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934\u2013949.e16 (2017). This study, along with Van Allen et al. (2015) and Germano et al. (2017), demonstrates the association between TMB and ICB responses in humans.","journal-title":"Cell"},{"key":"1312_CR58","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"1312_CR59","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy, S. P. et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature 615, 687\u2013696 (2023). This study provides a clinical report of CRISPR-mediated engineering of neoantigen-specific TCR-T cells for ACT in humans.","journal-title":"Nature"},{"key":"1312_CR60","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/978-1-0716-0795-4_30","volume":"2183","author":"B Akache","year":"2021","unstructured":"Akache, B. & McCluskie, M. J. The quantification of antigen-specific T cells by IFN-\u03b3 ELISpot. Methods Mol. Biol. 2183, 525\u2013536 (2021).","journal-title":"Methods Mol. Biol."},{"key":"1312_CR61","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1158\/1078-0432.CCR-16-2680","volume":"23","author":"M Parkhurst","year":"2017","unstructured":"Parkhurst, M. et al. Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression. Clin. Cancer Res. 23, 2491\u20132505 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0022-1759(03)00265-5","volume":"281","author":"MR Betts","year":"2003","unstructured":"Betts, M. R. et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281, 65\u201378 (2003).","journal-title":"J. Immunol. Methods"},{"key":"1312_CR63","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2012961","volume":"11","author":"S Li","year":"2022","unstructured":"Li, S. et al. Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct. Oncoimmunology 11, 2012961 (2022).","journal-title":"Oncoimmunology"},{"key":"1312_CR64","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.4049\/jimmunol.140.7.2453","volume":"140","author":"T Chou","year":"1988","unstructured":"Chou, T., Chang, A. E. & Shu, S. Y. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity. J. Immunol. 140, 2453\u20132461 (1988).","journal-title":"J. Immunol."},{"key":"1312_CR65","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1084\/jem.167.6.1767","volume":"167","author":"FR Carbone","year":"1988","unstructured":"Carbone, F. R., Moore, M. W., Sheil, J. M. & Bevan, M. J. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J. Exp. Med. 167, 1767\u20131779 (1988).","journal-title":"J. Exp. Med."},{"key":"1312_CR66","first-page":"4895","volume":"58","author":"MR Parkhurst","year":"1998","unstructured":"Parkhurst, M. R. et al. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58, 4895\u20134901 (1998).","journal-title":"Cancer Res."},{"key":"1312_CR67","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41587-021-01072-6","volume":"40","author":"M Arnaud","year":"2022","unstructured":"Arnaud, M. et al. Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nat. Biotechnol. 40, 656\u2013660 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1312_CR68","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1158\/1078-0432.CCR-21-0849","volume":"27","author":"N Levin","year":"2021","unstructured":"Levin, N. et al. Identification and validation of T-cell receptors targeting hotspot mutations in human cancers for use in cell-based immunotherapy. Clin. Cancer Res. 27, 5084\u20135095 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08304-z","volume":"10","author":"G Cafri","year":"2019","unstructured":"Cafri, G. et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat. Commun. 10, 449 (2019).","journal-title":"Nat. Commun."},{"key":"1312_CR70","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-19-1874","volume":"26","author":"P Malekzadeh","year":"2020","unstructured":"Malekzadeh, P. et al. Antigen experienced T cells from peripheral blood recognize p53 neoantigens. Clin. Cancer Res. 26, 1267\u20131276 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008645","volume":"12","author":"N Levin","year":"2024","unstructured":"Levin, N. et al. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes. J. Immunother. Cancer 12, e008645 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1312_CR72","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41592-018-0304-8","volume":"16","author":"AV Joglekar","year":"2019","unstructured":"Joglekar, A. V. et al. T cell antigen discovery via signaling and antigen-presenting bifunctional receptors. Nat. Methods 16, 191\u2013198 (2019).","journal-title":"Nat. Methods"},{"key":"1312_CR73","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41592-024-02255-0","volume":"21","author":"PM Zdinak","year":"2024","unstructured":"Zdinak, P. M. et al. De novo identification of CD4+ T cell epitopes. Nat. Methods 21, 846\u2013856 (2024).","journal-title":"Nat. Methods"},{"key":"1312_CR74","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41587-022-01547-0","volume":"41","author":"CM Cattaneo","year":"2023","unstructured":"Cattaneo, C. M. et al. Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens. Nat. Biotechnol. 41, 783\u2013787 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1312_CR75","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1172\/JCI82416","volume":"125","author":"CJ Cohen","year":"2015","unstructured":"Cohen, C. J. et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 125, 3981\u20133991 (2015).","journal-title":"J. Clin. Invest."},{"key":"1312_CR76","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/ijc.1580","volume":"97","author":"MJ Maeurer","year":"2002","unstructured":"Maeurer, M. J. et al. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A\/Mart-1 peptide analogue. Int. J. Cancer 97, 64\u201371 (2002).","journal-title":"Int. J. Cancer"},{"key":"1312_CR77","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/1078-0432.CCR-0620-3","volume":"10","author":"RH Vonderheide","year":"2004","unstructured":"Vonderheide, R. H. et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. 10, 828\u2013839 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR78","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1046\/j.1365-3083.2003.01324.x","volume":"58","author":"P Terheyden","year":"2003","unstructured":"Terheyden, P. et al. Longitudinal analysis of MART-1\/HLA-A2-reactive T cells over the course of melanoma progression. Scand. J. Immunol. 58, 566\u2013571 (2003).","journal-title":"Scand. J. Immunol."},{"key":"1312_CR79","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1172\/JCI98689","volume":"128","author":"JR Veatch","year":"2018","unstructured":"Veatch, J. R. et al. Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. J. Clin. Invest. 128, 1563\u20131568 (2018).","journal-title":"J. Clin. Invest."},{"key":"1312_CR80","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/nmeth.1345","volume":"6","author":"SR Hadrup","year":"2009","unstructured":"Hadrup, S. R. et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat. Methods 6, 520\u2013526 (2009). This study is one of the first reports of large-scale HLA-multimer-based isolation of antigen-specific T cells.","journal-title":"Nat. Methods"},{"key":"1312_CR81","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/nbt.3662","volume":"34","author":"AK Bentzen","year":"2016","unstructured":"Bentzen, A. K. et al. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nat. Biotechnol. 34, 1037\u20131045 (2016).","journal-title":"Nat. Biotechnol."},{"key":"1312_CR82","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/nprot.2006.121","volume":"1","author":"B Rodenko","year":"2006","unstructured":"Rodenko, B. et al. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat. Protoc. 1, 1120\u20131132 (2006).","journal-title":"Nat. Protoc."},{"key":"1312_CR83","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150535","volume":"132","author":"NP Kristensen","year":"2022","unstructured":"Kristensen, N. P. et al. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. J. Clin. Invest. 132, e150535 (2022).","journal-title":"J. Clin. Invest."},{"key":"1312_CR84","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.ccell.2023.11.005","volume":"41","author":"R Yossef","year":"2023","unstructured":"Yossef, R. et al. Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers. Cancer Cell 41, 2154\u20132165 (2023).","journal-title":"Cancer Cell"},{"key":"1312_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101390","volume":"5","author":"H Ryu","year":"2024","unstructured":"Ryu, H. et al. Merkel cell polyomavirus-specific and CD39+CLA+ CD8 T cells as blood-based predictive biomarkers for PD-1 blockade in Merkel cell carcinoma. Cell Rep. Med. 5, 101390 (2024).","journal-title":"Cell Rep. Med."},{"key":"1312_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13404","volume":"7","author":"M Bassani-Sternberg","year":"2016","unstructured":"Bassani-Sternberg, M. et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 7, 13404 (2016).","journal-title":"Nat. Commun."},{"key":"1312_CR87","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41587-021-01038-8","volume":"40","author":"C Chong","year":"2022","unstructured":"Chong, C., Coukos, G. & Bassani-Sternberg, M. Identification of tumor antigens with immunopeptidomics. Nat. Biotechnol. 40, 175\u2013188 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1312_CR88","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature02240","volume":"427","author":"K-I Hanada","year":"2004","unstructured":"Hanada, K.-I., Yewdell, J. W. & Yang, J. C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427, 252\u2013256 (2004).","journal-title":"Nature"},{"key":"1312_CR89","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5516","volume":"10","author":"CM Laumont","year":"2018","unstructured":"Laumont, C. M. et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci. Transl. Med. 10, eaau5516 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1312_CR90","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","volume":"46","author":"JG Abelin","year":"2017","unstructured":"Abelin, J. G. et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 46, 315\u2013326 (2017).","journal-title":"Immunity"},{"key":"1312_CR91","doi-asserted-by":"publisher","first-page":"29608","DOI":"10.1074\/jbc.M110.126722","volume":"285","author":"AB Riemer","year":"2010","unstructured":"Riemer, A. B. et al. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J. Biol. Chem. 285, 29608\u201329622 (2010).","journal-title":"J. Biol. Chem."},{"key":"1312_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007097","volume":"11","author":"CM Ade","year":"2023","unstructured":"Ade, C. M. et al. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics. J. Immunother. Cancer 11, e007097 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1312_CR93","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246\u20132259 (2014).","journal-title":"J. Clin. Invest."},{"key":"1312_CR94","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","volume":"22","author":"A Gros","year":"2016","unstructured":"Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433\u2013438 (2016).","journal-title":"Nat. Med."},{"key":"1312_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05072-0","volume":"9","author":"T Duhen","year":"2018","unstructured":"Duhen, T. et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat. Commun. 9, 2724 (2018).","journal-title":"Nat. Commun."},{"key":"1312_CR96","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","volume":"25","author":"W Scheper","year":"2019","unstructured":"Scheper, W. et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat. Med. 25, 89\u201394 (2019).","journal-title":"Nat. Med."},{"key":"1312_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006264","volume":"11","author":"PD Chatani","year":"2023","unstructured":"Chatani, P. D. et al. Cell surface marker-based capture of neoantigen-reactive CD8+ T-cell receptors from metastatic tumor digests. J. Immunother. Cancer 11, e006264 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1312_CR98","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.abb9847","volume":"370","author":"S Krishna","year":"2020","unstructured":"Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328\u20131334 (2020). This study demonstrates that stem-like neoantigen-specific TIL within TIL-ACT infusion products are associated with durable clinical responses in patients with metastatic melanoma.","journal-title":"Science"},{"key":"1312_CR99","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","volume":"176","author":"H Li","year":"2019","unstructured":"Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775\u2013789.e18 (2019).","journal-title":"Cell"},{"key":"1312_CR100","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM van der Leun","year":"2020","unstructured":"van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218\u2013232 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1312_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18158-5","volume":"11","author":"S Aldridge","year":"2020","unstructured":"Aldridge, S. & Teichmann, S. A. Single cell transcriptomics comes of age. Nat. Commun. 11, 4307 (2020).","journal-title":"Nat. Commun."},{"key":"1312_CR102","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1126\/science.abl5447","volume":"375","author":"FJ Lowery","year":"2022","unstructured":"Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877\u2013884 (2022).","journal-title":"Science"},{"key":"1312_CR103","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","volume":"596","author":"JX Caushi","year":"2021","unstructured":"Caushi, J. X. et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 596, 126\u2013132 (2021).","journal-title":"Nature"},{"key":"1312_CR104","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"1312_CR105","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","volume":"40","author":"K-I Hanada","year":"2022","unstructured":"Hanada, K.-I. et al. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell 40, 479\u2013493.e6 (2022). This study, along with Lowery et al. (2022), Caushi et al. (2021) and Oliveira et al. (2021), demonstrates that tumour-specific, neoantigen-specific TIL within human metastatic cancer deposits exhibits a unique transcriptional state.","journal-title":"Cancer Cell"},{"key":"1312_CR106","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ccell.2022.03.005","volume":"40","author":"C Zheng","year":"2022","unstructured":"Zheng, C. et al. Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. Cancer Cell 40, 410\u2013423.e7 (2022).","journal-title":"Cancer Cell"},{"key":"1312_CR107","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ccell.2022.03.006","volume":"40","author":"JR Veatch","year":"2022","unstructured":"Veatch, J. R. et al. Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function. Cancer Cell 40, 393\u2013409 (2022).","journal-title":"Cancer Cell"},{"key":"1312_CR108","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-022-04682-5","volume":"605","author":"G Oliveira","year":"2022","unstructured":"Oliveira, G. et al. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature 605, 532\u2013538 (2022).","journal-title":"Nature"},{"key":"1312_CR109","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41587-024-02161-y","volume":"43","author":"CL Tan","year":"2025","unstructured":"Tan, C. L. et al. Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy. Nat. Biotechnol. 43, 134\u2013142 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1312_CR110","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.21.02170","volume":"40","author":"N Zacharakis","year":"2022","unstructured":"Zacharakis, N. et al. Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J. Clin. Oncol. 40, 1741\u20131754 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1312_CR111","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","volume":"2","author":"AH Pearlman","year":"2021","unstructured":"Pearlman, A. H. et al. Targeting public neoantigens for cancer immunotherapy. Nat. Cancer 2, 487\u2013497 (2021).","journal-title":"Nat. Cancer"},{"key":"1312_CR112","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41586-022-04696-z","volume":"606","author":"D Hoyos","year":"2022","unstructured":"Hoyos, D. et al. Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature 606, 172\u2013179 (2022).","journal-title":"Nature"},{"key":"1312_CR113","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.181873","volume":"10","author":"X Xu","year":"2025","unstructured":"Xu, X. et al. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. JCI Insight 10, e181873 (2025).","journal-title":"JCI Insight"},{"key":"1312_CR114","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1158\/2326-6066.CIR-18-0686","volume":"7","author":"W Lo","year":"2019","unstructured":"Lo, W. et al. Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. Cancer Immunol. Res. 7, 534\u2013543 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1312_CR115","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41591-022-01786-3","volume":"28","author":"SS Chandran","year":"2022","unstructured":"Chandran, S. S. et al. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat. Med. 28, 946\u2013957 (2022).","journal-title":"Nat. Med."},{"key":"1312_CR116","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s43018-021-00197-6","volume":"2","author":"JJ Gartner","year":"2021","unstructured":"Gartner, J. J. et al. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. Nat. Cancer 2, 563\u2013574 (2021).","journal-title":"Nat. Cancer"},{"key":"1312_CR117","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.immuni.2023.09.002","volume":"56","author":"M M\u00fcller","year":"2023","unstructured":"M\u00fcller, M. et al. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction. Immunity 56, 2650\u20132663 (2023).","journal-title":"Immunity"},{"key":"1312_CR118","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells, D. K. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183, 818\u2013834.e13 (2020).","journal-title":"Cell"},{"key":"1312_CR119","doi-asserted-by":"publisher","first-page":"E1754","DOI":"10.1073\/pnas.1500973112","volume":"112","author":"D Chowell","year":"2015","unstructured":"Chowell, D. et al. TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc. Natl Acad. Sci. USA 112, E1754\u2013E1762 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1312_CR120","doi-asserted-by":"publisher","first-page":"12826","DOI":"10.1073\/pnas.1921964117","volume":"117","author":"MJW Sim","year":"2020","unstructured":"Sim, M. J. W. et al. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D. Proc. Natl Acad. Sci. USA 117, 12826\u201312835 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1312_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16755-y","volume":"11","author":"D Wu","year":"2020","unstructured":"Wu, D., Gallagher, D. T., Gowthaman, R., Pierce, B. G. & Mariuzza, R. A. Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen. Nat. Commun. 11, 2908 (2020).","journal-title":"Nat. Commun."},{"key":"1312_CR122","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","volume":"43","author":"F Huber","year":"2025","unstructured":"Huber, F. et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat. Biotechnol. 43, 1360\u20131372 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1312_CR123","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba7918","volume":"5","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. TOX is expressed by exhausted and polyfunctional human effector memory CD8+ T cells. Sci. Immunol. 5, eaba7918 (2020).","journal-title":"Sci. Immunol."},{"key":"1312_CR124","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1097\/QAD.0b013e3282eee548","volume":"21","author":"D Sauce","year":"2007","unstructured":"Sauce, D. et al. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 21, 2005\u20132013 (2007).","journal-title":"AIDS"},{"key":"1312_CR125","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nature09515","volume":"467","author":"S Yachida","year":"2010","unstructured":"Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114\u20131117 (2010).","journal-title":"Nature"},{"key":"1312_CR126","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1158\/1078-0432.CCR-11-0503","volume":"17","author":"CA Klebanoff","year":"2011","unstructured":"Klebanoff, C. A. et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17, 5343\u20135352 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR127","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","volume":"19","author":"MJ Besser","year":"2013","unstructured":"Besser, M. J. et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 19, 4792\u20134800 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR128","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.9516","volume":"43","author":"K Ward","year":"2025","unstructured":"Ward, K. et al. Infusion product characteristics to predict response to tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma (MM). J. Clin. Oncol. 43, 9516 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1312_CR129","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019\u20131027 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR130","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke, M. et al. Autologous T cell therapy for PRAME advanced solid tumors in HLA-A*02 patients: a phase 1 trial. Nat. Med. 31, 2365\u20132374 (2025).","journal-title":"Nat. Med."},{"key":"1312_CR131","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan, B. C. et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat. Med. 27, 1410\u20131418 (2021).","journal-title":"Nat. Med."},{"key":"1312_CR132","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577\u2013581 (2014).","journal-title":"Nature"},{"key":"1312_CR133","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nm.3773","volume":"21","author":"C Linnemann","year":"2015","unstructured":"Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81\u201385 (2015).","journal-title":"Nat. Med."},{"key":"1312_CR134","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007288","volume":"11","author":"MS Hall","year":"2023","unstructured":"Hall, M. S. et al. Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. J. Immunother. Cancer 11, e007288 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1312_CR135","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aao4310","volume":"4","author":"M Ahmadzadeh","year":"2019","unstructured":"Ahmadzadeh, M. et al. Tumor-infiltrating human CD4 regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. Sci. Immunol. 4, eaao4310 (2019).","journal-title":"Sci. Immunol."},{"key":"1312_CR136","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/cimm.2001.1809","volume":"210","author":"R Zennadi","year":"2001","unstructured":"Zennadi, R., Abdel-Wahab, Z., Seigler, H. F. & Darrow, T. L. Generation of melanoma-specific, cytotoxic CD4+ T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. Cell Immunol. 210, 96\u2013105 (2001).","journal-title":"Cell Immunol."},{"key":"1312_CR137","doi-asserted-by":"publisher","first-page":"6036","DOI":"10.4049\/jimmunol.169.10.6036","volume":"169","author":"PF Robbins","year":"2002","unstructured":"Robbins, P. F. et al. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. J. Immunol. 169, 6036\u20136047 (2002).","journal-title":"J. Immunol."},{"key":"1312_CR138","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"1312_CR139","doi-asserted-by":"publisher","first-page":"8633","DOI":"10.1073\/pnas.96.15.8633","volume":"96","author":"D Mumberg","year":"1999","unstructured":"Mumberg, D. et al. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-\u03b3. Proc. Natl Acad. Sci. USA 96, 8633\u20138638 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1312_CR140","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","volume":"618","author":"B Kruse","year":"2023","unstructured":"Kruse, B. et al. CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours. Nature 618, 1033\u20131040 (2023).","journal-title":"Nature"},{"key":"1312_CR141","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-22-3853","volume":"29","author":"A Draghi","year":"2023","unstructured":"Draghi, A. et al. Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma. Clin. Cancer Res. 29, 3937\u20133947 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR142","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723.e4 (2017).","journal-title":"Cancer Cell"},{"key":"1312_CR143","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.ccell.2021.10.008","volume":"39","author":"J Duraiswamy","year":"2021","unstructured":"Duraiswamy, J. et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell 39, 1623\u20131642.e20 (2021).","journal-title":"Cancer Cell"},{"key":"1312_CR144","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1016\/j.cell.2021.11.007","volume":"184","author":"C Cui","year":"2021","unstructured":"Cui, C. et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell 184, 6101\u20136118.e13 (2021).","journal-title":"Cell"},{"key":"1312_CR145","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip, M. & Schietinger, A. CD8+ T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 22, 209\u2013223 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1312_CR146","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41590-022-01229-8","volume":"23","author":"JT Crowl","year":"2022","unstructured":"Crowl, J. T. et al. Tissue-resident memory CD8+ T cells possess unique transcriptional, epigenetic and functional adaptations to different tissue environments. Nat. Immunol. 23, 1121\u20131131 (2022).","journal-title":"Nat. Immunol."},{"key":"1312_CR147","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.it.2019.06.002","volume":"40","author":"SL Park","year":"2019","unstructured":"Park, S. L., Gebhardt, T. & Mackay, L. K. Tissue-resident memory T cells in cancer immunosurveillance. Trends Immunol. 40, 735\u2013747 (2019).","journal-title":"Trends Immunol."},{"key":"1312_CR148","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto, M. et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu. Rev. Med. 69, 301\u2013318 (2018).","journal-title":"Annu. Rev. Med."},{"key":"1312_CR149","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"},{"key":"1312_CR150","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"AC Scott","year":"2019","unstructured":"Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270\u2013274 (2019). This study demonstrates that TOX is a major master regulator of T cell exhaustion genes.","journal-title":"Nature"},{"key":"1312_CR151","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187\u20132194 (2010).","journal-title":"J. Exp. Med."},{"key":"1312_CR152","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","volume":"50","author":"S Kurtulus","year":"2019","unstructured":"Kurtulus, S. et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1\u2212CD8 tumor-infiltrating T cells. Immunity 50, 181\u2013194 (2019).","journal-title":"Immunity"},{"key":"1312_CR153","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457\u2013495 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"1312_CR154","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nm.1982","volume":"15","author":"L Gattinoni","year":"2009","unstructured":"Gattinoni, L. et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15, 808\u2013813 (2009).","journal-title":"Nat. Med."},{"key":"1312_CR155","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/ni.3441","volume":"17","author":"R Roychoudhuri","year":"2016","unstructured":"Roychoudhuri, R. et al. BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers. Nat. Immunol. 17, 851\u2013860 (2016).","journal-title":"Nat. Immunol."},{"key":"1312_CR156","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1172\/JCI24480","volume":"115","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616\u20131626 (2005). This study demonstrates in murine models that less differentiated T cells are more efficacious in mediating antitumour responses than differentiated counterparts.","journal-title":"J. Clin. Invest."},{"key":"1312_CR157","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/blood-2010-05-286286","volume":"117","author":"CS Hinrichs","year":"2011","unstructured":"Hinrichs, C. S. et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808\u2013814 (2011).","journal-title":"Blood"},{"key":"1312_CR158","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290\u20131297 (2011).","journal-title":"Nat. Med."},{"key":"1312_CR159","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326\u2013336 (2019). This study demonstrates in murine models the presence of progenitor-exhausted T cell subsets as being critical for ICB responses.","journal-title":"Nat. Immunol."},{"key":"1312_CR160","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41590-021-00965-7","volume":"22","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. BATF regulates progenitor to cytolytic effector CD8+ T cell transition during chronic viral infection. Nat. Immunol. 22, 996\u20131007 (2021).","journal-title":"Nat. Immunol."},{"key":"1312_CR161","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","volume":"51","author":"WH Hudson","year":"2019","unstructured":"Hudson, W. H. et al. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1+ stem-like CD8+ T cells during chronic infection. Immunity 51, 1043\u20131058.e4 (2019).","journal-title":"Immunity"},{"key":"1312_CR162","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1172\/JCI127967","volume":"129","author":"A Gros","year":"2019","unstructured":"Gros, A. et al. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. J. Clin. Invest. 129, 4992\u20135004 (2019).","journal-title":"J. Clin. Invest."},{"key":"1312_CR163","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994\u20131004 (2018).","journal-title":"Nat. Med."},{"key":"1312_CR164","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005177","volume":"11","author":"PK Gupta","year":"2015","unstructured":"Gupta, P. K. et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog. 11, e1005177 (2015).","journal-title":"PLoS Pathog."},{"key":"1312_CR165","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.4049\/jimmunol.175.10.7046","volume":"175","author":"J Zhou","year":"2005","unstructured":"Zhou, J. et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046\u20137052 (2005).","journal-title":"J. Immunol."},{"key":"1312_CR166","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/01.cji.0000211321.07654.b8","volume":"30","author":"X Shen","year":"2007","unstructured":"Shen, X. et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. 30, 123\u2013129 (2007).","journal-title":"J. Immunother."},{"key":"1312_CR167","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550\u20134557 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR168","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/CJI.0b013e31818403d5","volume":"31","author":"KQ Tran","year":"2008","unstructured":"Tran, K. Q. et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 31, 742\u2013751 (2008).","journal-title":"J. Immunother."},{"key":"1312_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.12.034","volume":"176","author":"M Sade-Feldman","year":"2019","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 176, 404 (2019).","journal-title":"Cell"},{"key":"1312_CR170","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"1312_CR171","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2021.06.013","volume":"54","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 54, 1825\u20131840.e7 (2021).","journal-title":"Immunity"},{"key":"1312_CR172","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1158\/2159-8290.CD-21-1248","volume":"12","author":"A Schalck","year":"2022","unstructured":"Schalck, A. et al. Single-cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer. Cancer Discov. 12, 2330\u20132349 (2022).","journal-title":"Cancer Discov."},{"key":"1312_CR173","doi-asserted-by":"publisher","first-page":"7125","DOI":"10.4049\/jimmunol.173.12.7125","volume":"173","author":"PF Robbins","year":"2004","unstructured":"Robbins, P. F. et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125\u20137130 (2004).","journal-title":"J. Immunol."},{"key":"1312_CR174","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/01.cji.0000158855.92792.7a","volume":"28","author":"J Huang","year":"2005","unstructured":"Huang, J. et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28, 258\u2013267 (2005).","journal-title":"J. Immunother."},{"key":"1312_CR175","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","volume":"22","author":"R Andersen","year":"2016","unstructured":"Andersen, R. et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin. Cancer Res. 22, 3734\u20133745 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR176","doi-asserted-by":"publisher","first-page":"16168","DOI":"10.1073\/pnas.242600099","volume":"99","author":"C Yee","year":"2002","unstructured":"Yee, C. et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99, 16168\u201316173 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1312_CR177","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","volume":"33","author":"S Stevanovi\u0107","year":"2015","unstructured":"Stevanovi\u0107, S. et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J. Clin. Oncol. 33, 1543\u20131550 (2015). This study is one of the first clinical reports on TIL-ACT targeting HPV-driven cancers.","journal-title":"J. Clin. Oncol."},{"key":"1312_CR178","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","volume":"25","author":"S Stevanovi\u0107","year":"2019","unstructured":"Stevanovi\u0107, S. et al. A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin. Cancer Res. 25, 1486\u20131493 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR179","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/2326-6066.CIR-19-0299","volume":"7","author":"Y-C Lu","year":"2019","unstructured":"Lu, Y.-C. et al. Single-cell transcriptome analysis reveals gene signatures associated with T-cell persistence following adoptive cell therapy. Cancer Immunol. Res. 7, 1824\u20131836 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1312_CR180","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2004-06-2482","volume":"105","author":"DJ Powell Jr","year":"2005","unstructured":"Powell, D. J. Jr, Dudley, M. E., Robbins, P. F. & Rosenberg, S. A. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105, 241\u2013250 (2005).","journal-title":"Blood"},{"key":"1312_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32491-x","volume":"13","author":"A Gyurdieva","year":"2022","unstructured":"Gyurdieva, A. et al. Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. Nat. Commun. 13, 5296 (2022).","journal-title":"Nat. Commun."},{"key":"1312_CR182","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","volume":"8","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo, S. P. et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 T cells in synovial sarcoma. Cancer Discov. 8, 944\u2013957 (2018).","journal-title":"Cancer Discov."},{"key":"1312_CR183","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1200\/JCO.18.02424","volume":"37","author":"SL Doran","year":"2019","unstructured":"Doran, S. L. et al. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study. J. Clin. Oncol. 37, 2759\u20132768 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1312_CR184","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419\u2013425 (2021).","journal-title":"Nat. Med."},{"key":"1312_CR185","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-18-3496","volume":"25","author":"TS Nowicki","year":"2019","unstructured":"Nowicki, T. S. et al. A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab. Clin. Cancer Res. 25, 2096\u20132108 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR186","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1146\/annurev.immunol.16.1.523","volume":"16","author":"MM Davis","year":"1998","unstructured":"Davis, M. M. et al. Ligand recognition by \u03b1\u03b2 T cell receptors. Annu. Rev. Immunol. 16, 523\u2013544 (1998).","journal-title":"Annu. Rev. Immunol."},{"key":"1312_CR187","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.4049\/jimmunol.1000173","volume":"184","author":"DA Schmid","year":"2010","unstructured":"Schmid, D. A. et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 184, 4936\u20134946 (2010).","journal-title":"J. Immunol."},{"key":"1312_CR188","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/PPO.0000000000000160","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins, P. F. T-cell receptor-transduced T cells: clinical experience. Cancer J. 21, 480\u2013485 (2015).","journal-title":"Cancer J."},{"key":"1312_CR189","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1182\/blood-2009-01-199216","volume":"114","author":"WR Burns","year":"2009","unstructured":"Burns, W. R., Zheng, Z., Rosenberg, S. A. & Morgan, R. A. Lack of specific \u03b3-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 114, 2888\u20132899 (2009).","journal-title":"Blood"},{"key":"1312_CR190","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.4049\/jimmunol.1101268","volume":"187","author":"OY Borbulevych","year":"2011","unstructured":"Borbulevych, O. Y., Santhanagopolan, S. M., Hossain, M. & Baker, B. M. TCRs used in cancer gene therapy cross-react with MART-1\/Melan-A tumor antigens via distinct mechanisms. J. Immunol. 187, 2453\u20132463 (2011).","journal-title":"J. Immunol."},{"key":"1312_CR191","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.4049\/jimmunol.180.9.6116","volume":"180","author":"PF Robbins","year":"2008","unstructured":"Robbins, P. F. et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180, 6116\u20136131 (2008).","journal-title":"J. Immunol."},{"key":"1312_CR192","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ymthe.2018.12.010","volume":"27","author":"LM Hellman","year":"2019","unstructured":"Hellman, L. M. et al. Improving T cell receptor on-target specificity via structure-guided design. Mol. Ther. 27, 300\u2013313 (2019).","journal-title":"Mol. Ther."},{"key":"1312_CR193","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","volume":"25","author":"AG Chapuis","year":"2019","unstructured":"Chapuis, A. G. et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat. Med. 25, 1064\u20131072 (2019).","journal-title":"Nat. Med."},{"key":"1312_CR194","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133\u2013151 (2013).","journal-title":"J. Immunother."},{"key":"1312_CR195","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1073\/pnas.91.14.6458","volume":"91","author":"Y Kawakami","year":"1994","unstructured":"Kawakami, Y. et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA 91, 6458\u20136462 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1312_CR196","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G. P. et al. Cardiovascular toxicity and Titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863\u2013871 (2013).","journal-title":"Blood"},{"key":"1312_CR197","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron, B. J. et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1312_CR198","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.1073\/pnas.1221609110","volume":"110","author":"S Zhong","year":"2013","unstructured":"Zhong, S. et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc. Natl Acad. Sci. USA 110, 6973\u20136978 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1312_CR199","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2015.01.003","volume":"33","author":"JD Stone","year":"2015","unstructured":"Stone, J. D., Harris, D. T. & Kranz, D. M. TCR affinity for p\/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr. Opin. Immunol. 33, 16\u201322 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"1312_CR200","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ni863","volume":"4","author":"PD Holler","year":"2003","unstructured":"Holler, P. D., Chlewicki, L. K. & Kranz, D. M. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4, 55\u201362 (2003).","journal-title":"Nat. Immunol."},{"key":"1312_CR201","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2326-6066.CIR-18-0371","volume":"7","author":"AM Miller","year":"2019","unstructured":"Miller, A. M., Bahmanof, M., Zehn, D., Cohen, E. E. W. & Schoenberger, S. P. Leveraging TCR affinity in adoptive immunotherapy against shared tumor\/self-antigens. Cancer Immunol. Res. 7, 40\u201349 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1312_CR202","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201966","volume":"219","author":"M Shakiba","year":"2022","unstructured":"Shakiba, M. et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J. Exp. Med. 219, e20201966 (2022).","journal-title":"J. Exp. Med."},{"key":"1312_CR203","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.4049\/jimmunol.174.5.2563","volume":"174","author":"MA Lyman","year":"2005","unstructured":"Lyman, M. A. et al. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J. Immunol. 174, 2563\u20132572 (2005).","journal-title":"J. Immunol."},{"key":"1312_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38946-z","volume":"14","author":"J Schmidt","year":"2023","unstructured":"Schmidt, J. et al. Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors. Nat. Commun. 14, 3188 (2023).","journal-title":"Nat. Commun."},{"key":"1312_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss, M. et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat. Commun. 8, 1738 (2017).","journal-title":"Nat. Commun."},{"key":"1312_CR206","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1158\/1078-0432.CCR-21-1060","volume":"28","author":"CA Creasy","year":"2022","unstructured":"Creasy, C. A. et al. Genomic correlates of outcome in tumor-infiltrating lymphocyte therapy for metastatic melanoma. Clin. Cancer Res. 28, 1911\u20131924 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR207","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1200\/JCO-25-00765","volume":"43","author":"T Medina","year":"2025","unstructured":"Medina, T. et al. Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study. J. Clin. Oncol. 43, 3565\u20133572 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1312_CR208","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.aad1253","volume":"350","author":"E Tran","year":"2015","unstructured":"Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387\u20131390 (2015).","journal-title":"Science"},{"key":"1312_CR209","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","volume":"25","author":"W Yang","year":"2019","unstructured":"Yang, W. et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat. Med. 25, 767\u2013775 (2019).","journal-title":"Nat. Med."},{"key":"1312_CR210","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal, D., Gubin, M. M., Schreiber, R. D. & Smyth, M. J. New insights into cancer immunoediting and its three component phases \u2014 elimination, equilibrium and escape. Curr. Opin. Immunol. 27, 16\u201325 (2014).","journal-title":"Curr. Opin. Immunol."},{"key":"1312_CR211","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41577-025-01208-8","volume":"26","author":"F Huber","year":"2026","unstructured":"Huber, F. & Bassani-Sternberg, M. Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development. Nat. Rev. Immunol. 26, 23\u201334 (2026).","journal-title":"Nat. Rev. Immunol."},{"key":"1312_CR212","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00262-002-0296-0","volume":"51","author":"I Maleno","year":"2002","unstructured":"Maleno, I., L\u00f3pez-Nevot, M. A., Cabrera, T., Salinero, J. & Garrido, F. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol. Immunother. 51, 389\u2013396 (2002).","journal-title":"Cancer Immunol. Immunother."},{"key":"1312_CR213","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/jnci\/djt184","volume":"105","author":"P Leone","year":"2013","unstructured":"Leone, P. et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J. Natl Cancer Inst. 105, 1172\u20131187 (2013).","journal-title":"J. Natl Cancer Inst."},{"key":"1312_CR214","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071760","volume":"12","author":"AM Cornel","year":"2020","unstructured":"Cornel, A. M., Mimpen, I. L. & Nierkens, S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers 12, 1760 (2020).","journal-title":"Cancers"},{"key":"1312_CR215","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259\u20131271 (2017).","journal-title":"Cell"},{"key":"1312_CR216","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479\u2013485 (2019). This study demonstrates in longitudinal human lung cancer samples the wide prevalence of HLA-loss and copy number alterations that mediate escape from immune surveillance.","journal-title":"Nature"},{"key":"1312_CR217","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","volume":"11","author":"M Montesion","year":"2021","unstructured":"Montesion, M. et al. Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 11, 282\u2013292 (2021).","journal-title":"Cancer Discov."},{"key":"1312_CR218","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00251-018-1074-2","volume":"70","author":"MA Garrido","year":"2018","unstructured":"Garrido, M. A. et al. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15. Immunogenetics 70, 647\u2013659 (2018).","journal-title":"Immunogenetics"},{"key":"1312_CR219","volume":"13","author":"L von Boehmer","year":"2013","unstructured":"von Boehmer, L. et al. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. Cancer Immun. 13, 12 (2013).","journal-title":"Cancer Immun."},{"key":"1312_CR220","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1158\/2159-8290.CD-20-0987","volume":"11","author":"G Germano","year":"2021","unstructured":"Germano, G. et al. CD4 T cell-dependent rejection of beta-2 microglobulin null mismatch repair-deficient tumors. Cancer Discov. 11, 1844\u20131859 (2021).","journal-title":"Cancer Discov."},{"key":"1312_CR221","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00321","volume":"3","author":"S Middha","year":"2019","unstructured":"Middha, S. et al. Majority of B2M-mutant and -deficient colorectal carcinomas achieve clinical benefit from immune checkpoint inhibitor therapy and are microsatellite instability-high. JCO Precis. Oncol. 3, 1\u201314 (2019).","journal-title":"JCO Precis. Oncol."},{"key":"1312_CR222","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1158\/2326-6066.CIR-23-0139","volume":"11","author":"DY Torrejon","year":"2023","unstructured":"Torrejon, D. Y. et al. Antitumor immune responses in B2M-deficient cancers. Cancer Immunol. Res. 11, 1642\u20131655 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"1312_CR223","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006303","volume":"11","author":"BS White","year":"2023","unstructured":"White, B. S. et al. Specific recognition of an fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma. J. Immunother. Cancer 11, e006303 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1312_CR224","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41586-021-03368-8","volume":"592","author":"S Kalaora","year":"2021","unstructured":"Kalaora, S. et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 592, 138\u2013143 (2021).","journal-title":"Nature"},{"key":"1312_CR225","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41587-021-01021-3","volume":"40","author":"T Ouspenskaia","year":"2022","unstructured":"Ouspenskaia, T. et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat. Biotechnol. 40, 209\u2013217 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1312_CR226","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1182\/blood.V98.10.2887","volume":"98","author":"RE Clark","year":"2001","unstructured":"Clark, R. E. et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98, 2887\u20132893 (2001).","journal-title":"Blood"},{"key":"1312_CR227","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2017.11.043","volume":"172","author":"MH Gee","year":"2018","unstructured":"Gee, M. H. et al. Antigen identification for orphan T cell receptors expressed on tumor-infiltrating lymphocytes. Cell 172, 549\u2013563 (2018).","journal-title":"Cell"},{"key":"1312_CR228","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2019.07.009","volume":"178","author":"T Kula","year":"2019","unstructured":"Kula, T. et al. T-Scan: a genome-wide method for the systematic discovery of T cell epitopes. Cell 178, 1016\u20131028 (2019).","journal-title":"Cell"},{"key":"1312_CR229","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg7836","volume":"6","author":"KA Connolly","year":"2021","unstructured":"Connolly, K. A. et al. A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci. Immunol. 6, eabg7836 (2021).","journal-title":"Sci. Immunol."},{"key":"1312_CR230","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41590-021-00975-5","volume":"22","author":"MS Abdel-Hakeem","year":"2021","unstructured":"Abdel-Hakeem, M. S. et al. Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. Nat. Immunol. 22, 1008\u20131019 (2021).","journal-title":"Nat. Immunol."},{"key":"1312_CR231","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41590-021-00979-1","volume":"22","author":"KB Yates","year":"2021","unstructured":"Yates, K. B. et al. Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. Nat. Immunol. 22, 1020\u20131029 (2021).","journal-title":"Nat. Immunol."},{"key":"1312_CR232","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41590-020-00817-w","volume":"22","author":"N Hensel","year":"2021","unstructured":"Hensel, N. et al. Memory-like HCV-specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection. Nat. Immunol. 22, 229\u2013239 (2021).","journal-title":"Nat. Immunol."},{"key":"1312_CR233","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"1312_CR234","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"1312_CR235","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan, A. E. et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature 629, 211\u2013218 (2024).","journal-title":"Nature"},{"key":"1312_CR236","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","volume":"40","author":"DD Klysz","year":"2024","unstructured":"Klysz, D. D. et al. Inosine induces stemness features in CAR T cells and enhances potency. Cancer Cell 40, 266\u2013282.e8 (2024).","journal-title":"Cancer Cell"},{"key":"1312_CR237","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jcyt.2024.12.010","volume":"27","author":"RN Amaria","year":"2025","unstructured":"Amaria, R. N. et al. Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation. Cytotherapy 27, 864\u2013873 (2025).","journal-title":"Cytotherapy"},{"key":"1312_CR238","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1073\/pnas.1422916112","volume":"112","author":"Y Ji","year":"2015","unstructured":"Ji, Y. et al. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic \u03b3c cytokines. Proc. Natl Acad. Sci. USA 112, 476\u2013481 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1312_CR239","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163096","volume":"133","author":"MR Schlabach","year":"2023","unstructured":"Schlabach, M. R. et al. Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR\/Cas9 screens. J. Clin. Invest. 133, e163096 (2023).","journal-title":"J. Clin. Invest."},{"key":"1312_CR240","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.medj.2022.07.008","volume":"3","author":"DC Palmer","year":"2022","unstructured":"Palmer, D. C. et al. Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. Med 3, 682\u2013704.e8 (2022).","journal-title":"Med"},{"key":"1312_CR241","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-sitc2022.0776","author":"J Ward","year":"2022","unstructured":"Ward, J. et al. 776 ITIL-306\u2013201: a multicenter, first-in-human phase 1a\/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2022-sitc2022.0776 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1312_CR242","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1172","volume":"31","author":"K Ritthipichai","year":"2020","unstructured":"Ritthipichai, K. et al. 1052P genetic modification of Iovance\u2019s TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer. Ann. Oncol. 31, S720 (2020).","journal-title":"Ann. Oncol."},{"key":"1312_CR243","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","volume":"24","author":"CA Chamberlain","year":"2022","unstructured":"Chamberlain, C. A. et al. Highly efficient PD-1-targeted CRISPR\u2013Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Mol. Ther. Oncolytics 24, 417\u2013428 (2022).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1312_CR244","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.9515","volume":"42","author":"JL McQuade","year":"2024","unstructured":"McQuade, J. L. et al. OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma. J. Clin. Oncol. 42, 9515 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1312_CR245","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(25)00083-X","volume":"26","author":"E Lou","year":"2025","unstructured":"Lou, E. et al. Targeting the intracellular immune checkpoint CISH with CRISPR\u2013Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncol. 26, 559\u2013570 (2025).","journal-title":"Lancet Oncol."},{"key":"1312_CR246","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.9517","volume":"43","author":"JA Chesney","year":"2025","unstructured":"Chesney, J. A. et al. OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy with regulatable membrane-bound IL15 (mbIL15) in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced melanoma: phase 1 results of the Agni-01 multicenter study. J. Clin. Oncol. 43, 9517 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1312_CR247","first-page":"403","volume":"11","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y., Gilbert, N., Innamarato, P., Fang, J. & Yin, H. Tumor-infiltrating lymphocytes (TIL) with inducible and membrane-bound IL-12 exhibit superior antitumor activity in vitro. J. Immunother. Cancer 11, 403 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1312_CR248","first-page":"366","volume":"12","author":"MD Crowther","year":"2024","unstructured":"Crowther, M. D., Svane, I. M. & Met, \u00d6. CRISPR\u2013Cas9 mediated double gene knockout of immune checkpoints PD1 and CISH in tumour-infiltrating T-cells. J. Immunother. Cancer 12, 366 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1312_CR249","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124405","volume":"4","author":"K-I Hanada","year":"2019","unstructured":"Hanada, K.-I., Yu, Z., Chappell, G. R., Park, A. S. & Restifo, N. P. An effective mouse model for adoptive cancer immunotherapy targeting neoantigens. JCI Insight 4, e124405 (2019).","journal-title":"JCI Insight"},{"key":"1312_CR250","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2326-6066.CIR-22-0978","volume":"12","author":"DJ Drakes","year":"2024","unstructured":"Drakes, D. J. et al. Lymph node-targeted vaccine boosting of TCR T-cell therapy enhances antitumor function and eradicates solid tumors. Cancer Immunol. Res. 12, 214\u2013231 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"1312_CR251","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","volume":"22","author":"Y Guo","year":"2021","unstructured":"Guo, Y. et al. Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. Nat. Immunol. 22, 746\u2013756 (2021).","journal-title":"Nat. Immunol."},{"key":"1312_CR252","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc.2017.36","volume":"17","author":"CV Dang","year":"2017","unstructured":"Dang, C. V., Reddy, E. P., Shokat, K. M. & Soucek, L. Drugging the \u2018undruggable\u2019 cancer targets. Nat. Rev. Cancer 17, 502\u2013508 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1312_CR253","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 619, 160\u2013166 (2023).","journal-title":"Nature"},{"key":"1312_CR254","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/1078-0432.CCR-16-0906","volume":"23","author":"DC Deniger","year":"2017","unstructured":"Deniger, D. C. et al. A pilot trial of the combination of vemurafenib with adoptive cell therapy in patients with metastatic melanoma. Clin. Cancer Res. 23, 351\u2013362 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1312_CR255","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002703","volume":"9","author":"TH Borch","year":"2021","unstructured":"Borch, T. H. et al. Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. J. Immunother. Cancer 9, e002703 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1312_CR256","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.4049\/jimmunol.172.10.6057","volume":"172","author":"J Huang","year":"2004","unstructured":"Huang, J. et al. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J. Immunol. 172, 6057\u20136064 (2004).","journal-title":"J. Immunol."},{"key":"1312_CR257","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/2326-6066.CIR-15-0188","volume":"4","author":"QJ Wang","year":"2016","unstructured":"Wang, Q. J. et al. Identification of T-cell receptors targeting KRAS-mutated human tumors. Cancer Immunol. Res. 4, 204\u2013214 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"1312_CR258","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.4049\/jimmunol.168.9.4802","volume":"168","author":"B Linard","year":"2002","unstructured":"Linard, B. et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J. Immunol. 168, 4802\u20134808 (2002).","journal-title":"J. Immunol."},{"key":"1312_CR259","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI123791","volume":"129","author":"P Malekzadeh","year":"2019","unstructured":"Malekzadeh, P. et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J. Clin. Invest. 129, 1109\u20131114 (2019).","journal-title":"J. Clin. Invest."},{"key":"1312_CR260","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28836","volume":"3","author":"MM van Buuren","year":"2014","unstructured":"van Buuren, M. M., Calis, J. J. & Schumacher, T. N. High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. Oncoimmunology 3, e28836 (2014).","journal-title":"Oncoimmunology"},{"key":"1312_CR261","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg, S. A., Spiess, P. & Lafreniere, R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318\u20131321 (1986).","journal-title":"Science"},{"key":"1312_CR262","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676\u20131680 (1988). This study provides a report of TIL-ACT being used to treat patients with human metastatic cancer.","journal-title":"N. Engl. J. Med."},{"key":"1312_CR263","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev.iy.12.040194.002005","volume":"12","author":"T Boon","year":"1994","unstructured":"Boon, T., Cerottini, J. C., Van den Eynde, B., van der Bruggen, P. & Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337\u2013365 (1994).","journal-title":"Annu. Rev. Immunol."},{"key":"1312_CR264","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1076514","volume":"298","author":"ME Dudley","year":"2002","unstructured":"Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850\u2013854 (2002).","journal-title":"Science"},{"key":"1312_CR265","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126\u2013129 (2006).","journal-title":"Science"},{"key":"1312_CR266","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535\u2013546 (2009).","journal-title":"Blood"},{"key":"1312_CR267","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/mt.2015.60","volume":"23","author":"JH van den Berg","year":"2015","unstructured":"van den Berg, J. H. et al. Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor. Mol. Ther. 23, 1541\u20131550 (2015).","journal-title":"Mol. Ther."},{"key":"1312_CR268","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst, M. R. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620\u2013626 (2011).","journal-title":"Mol. Ther."},{"key":"1312_CR269","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.196","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard, A. FDA approves first CAR T therapy. Nat. Rev. Drug Discov. 16, 669 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1312_CR270","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099\u20134102 (2010).","journal-title":"Blood"},{"key":"1312_CR271","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01312-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:01:20Z","timestamp":1793106080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01312-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":271,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1038\/s41577-026-01312-3","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"1 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}